Common Contracts
3 similar License Agreement contracts by SpringWorks Therapeutics, Inc.
EXECUTION VERSION CONFIDENTIAL AMENDED AND RESTATED LICENSE AGREEMENT by and among SpringWorks Subsidiary 3, Inc., Pfizer Inc., Warner-Lambert Company LLC, and, solely for purposes of Article 11 and Sections 3.2 and 3.3 hereof, SpringWorks...License Agreement • May 5th, 2020 • New York
AMENDED AND RESTATED LICENSE AGREEMENT by and among SpringWorks Subsidiary 2, Inc., Pfizer Inc., Pfizer Products Inc. and, solely for purposes of Article 11 and Sections 3.2 and 3.3 hereof, SpringWorks Therapeutics, Inc., as of July 31, 2019License Agreement • August 16th, 2019 • SpringWorks Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
THIS AMENDED AND RESTATED LICENSE AGREEMENT (“Agreement”) is made effective as of the 31ST day of July, 2019 (the “Amendment Effective Date”), by and among SpringWorks Subsidiary 2, Inc., a corporation organized and existing under the laws of Delaware with offices at 100 Washington Blvd., 5th Floor, Stamford, CT 06902 (“Licensee”), Pfizer Inc., a corporation organized and existing under the laws of Delaware with offices at 235 East 42nd Street, New York, NY 10017 (“Pfizer Inc.”), Pfizer Products Inc., a corporation organized and existing under the laws of Delaware with offices at 235 East 42nd Street, New York, NY 10017 (“PPI” and, collectively with Pfizer Inc., “Pfizer”) and , solely with respect to Article 11 and Sections 3.2 and 3.3, SpringWorks Therapeutics, Inc., a Delaware corporation (“SpringWorks”). Licensee and Pfizer may, from time-to-time, be individually referred to as a “Party” and collectively referred to as the “Parties”.
AMENDED AND RESTATED LICENSE AGREEMENT by and among SpringWorks Subsidiary 3, Inc., Pfizer Inc., Warner-Lambert Company LLC, and, solely for purposes of Article 11 and Sections 3.2 and 3.3 hereof, SpringWorks Therapeutics, Inc. as of August 7, 2019License Agreement • August 16th, 2019 • SpringWorks Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
THIS AMENDED AND RESTATED LICENSE AGREEMENT (“Agreement”) is made effective as of the 7th day of August, 2019 (the “Amendment Effective Date”), by and among SpringWorks Subsidiary 3, Inc., a corporation organized and existing under the laws of Delaware with offices at 100 Washington Blvd., 5th Floor, Stamford, CT 06902 (“Licensee”), Pfizer Inc., a corporation organized and existing under the laws of Delaware with offices at 235 East 42nd Street, New York, NY 10017 (“Pfizer Inc.”), Warner-Lambert Company LLC, a limited liability company organized and existing under the laws of Delaware with offices at 235 East 42nd Street, New York, NY 10017 (“Warner-Lambert” and, collectively with “Pfizer Inc.”, “Pfizer”) and, solely with respect to Article 11 and Sections 3.2 and 3.3, SpringWorks Therapeutics, Inc., a corporation organized and existing under the laws of Delaware (“SpringWorks”). Licensee and Pfizer may, from time-to-time, be individually referred to as a “Party” and collectively refer
